MX2009005335A - El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. - Google Patents

El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.

Info

Publication number
MX2009005335A
MX2009005335A MX2009005335A MX2009005335A MX2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A
Authority
MX
Mexico
Prior art keywords
treatment
manufacture
pregnane
cns disorders
pharmaceutical composition
Prior art date
Application number
MX2009005335A
Other languages
English (en)
Inventor
Torbjoern Baeckstroem
Gianna Ragagnin
Original Assignee
Umecrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab filed Critical Umecrine Ab
Publication of MX2009005335A publication Critical patent/MX2009005335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos esferoidales que tienen resistencia creciente contra el metabolismo y solubilidad creciente en agua, junto con métodos para su producción. Estas sustancias son adecuadas para la fabricación de productos farmacéuticos para el tratamiento de trastornos del SNC inducidos por esteroides o relacionados con esteroides y para uso en métodos de prevención, alivio o tratamiento de dichos trastornos.
MX2009005335A 2006-11-21 2007-11-20 El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. MX2009005335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
PCT/SE2007/050876 WO2008063128A1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2009005335A true MX2009005335A (es) 2009-06-08

Family

ID=39429970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005335A MX2009005335A (es) 2006-11-21 2007-11-20 El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.

Country Status (16)

Country Link
US (9) US8580983B2 (es)
EP (4) EP2097437B1 (es)
JP (5) JP5386362B2 (es)
AU (1) AU2007322423C1 (es)
BR (2) BRPI0718945B8 (es)
CA (2) CA2664126C (es)
DK (3) DK2711371T3 (es)
ES (3) ES2607852T3 (es)
HU (3) HUE036410T2 (es)
IN (1) IN2014DN02014A (es)
MX (1) MX2009005335A (es)
PL (3) PL2792681T3 (es)
PT (1) PT2097437E (es)
RU (1) RU2458065C2 (es)
SI (1) SI2097437T1 (es)
WO (1) WO2008063128A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2711371T3 (en) 2006-11-21 2018-04-16 Asarina Pharma Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
ES2566765T3 (es) 2010-01-14 2016-04-15 Asarina Pharma Ab Una composición farmacéutica que contiene 3-beta-hidroxi-5-alfa-pregnan-20-ona con propiedades de almacenamiento y solubilidad mejoradas
WO2011138460A1 (en) * 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof
US10259839B2 (en) * 2012-11-28 2019-04-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone
SI3461834T1 (sl) 2013-03-13 2021-11-30 Sage Therapeutics, Inc. Nevroaktivni steroidi
MX2016008851A (es) * 2014-01-29 2017-03-23 Umecrine Cognition Ab Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
SI3224269T1 (sl) * 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
WO2017007840A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
PL3436022T3 (pl) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
WO2018075698A1 (en) 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
BR112019015362A2 (pt) 2017-02-10 2020-10-20 Asarina Pharma Ab 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico
MX2020005442A (es) 2017-11-27 2022-03-30 Umecrine Cognition Ab FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.
MX2020010219A (es) 2018-04-05 2020-11-09 Asarina Pharma Aps Antagonistas de gaba-a para tratar trastornos por abstinencia de sustancia.
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
CA3237550A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) * 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
NZ282939A (en) * 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CN1171114A (zh) * 1994-11-23 1998-01-21 科斯赛斯公司 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
ATE284895T1 (de) * 1995-06-06 2005-01-15 Euro Celtique Sa Neuroaktive steroide der androstan- und pregnanreihe
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
ATE307592T1 (de) 1998-03-11 2005-11-15 Torbjoern Backstroem Epiallopregnanolon zur behandlung von krankheiten des cns
WO1999052532A1 (en) 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
FR2831441B1 (fr) 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
CA2585359C (en) * 2004-11-18 2013-01-08 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders
DK2711371T3 (en) 2006-11-21 2018-04-16 Asarina Pharma Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders
WO2011138460A1 (en) 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof

Also Published As

Publication number Publication date
HUE033037T2 (hu) 2017-11-28
AU2007322423C1 (en) 2013-08-15
PL2792681T3 (pl) 2017-06-30
PL2097437T3 (pl) 2015-12-31
JP5657052B2 (ja) 2015-01-21
EP2097437A1 (en) 2009-09-09
PT2097437E (pt) 2015-09-15
EP2792681B1 (en) 2016-10-19
US20140011779A1 (en) 2014-01-09
US20140011793A1 (en) 2014-01-09
BRPI0718945B8 (pt) 2021-05-25
US20080119416A1 (en) 2008-05-22
BRPI0718945B1 (pt) 2020-10-13
US9200028B2 (en) 2015-12-01
BRPI0718945A8 (pt) 2017-09-19
BRPI0718945A2 (pt) 2013-12-24
CA2664126C (en) 2014-04-29
EP2711371A1 (en) 2014-03-26
AU2007322423A1 (en) 2008-05-29
RU2009107537A (ru) 2010-12-27
DK2097437T3 (en) 2015-06-29
JP5386362B2 (ja) 2014-01-15
CA2833976C (en) 2016-03-15
EP2097437A4 (en) 2012-12-26
WO2008063128A1 (en) 2008-05-29
US20130281421A1 (en) 2013-10-24
JP2013177411A (ja) 2013-09-09
US20160272670A1 (en) 2016-09-22
ES2607852T3 (es) 2017-04-04
ES2543841T3 (es) 2015-08-24
PL2711371T3 (pl) 2018-06-29
EP2711372A1 (en) 2014-03-26
EP2792681A1 (en) 2014-10-22
DK2711371T3 (en) 2018-04-16
US8853190B2 (en) 2014-10-07
SI2097437T1 (sl) 2015-10-30
JP2013173782A (ja) 2013-09-05
BR122013033954B8 (pt) 2021-05-25
EP2711371B1 (en) 2018-01-10
US20130102579A1 (en) 2013-04-25
US20140011792A1 (en) 2014-01-09
DK2792681T3 (en) 2017-01-23
US20130102578A1 (en) 2013-04-25
CA2664126A1 (en) 2008-05-29
HUE026961T2 (en) 2016-07-28
IN2014DN02014A (es) 2015-07-10
JP2015147774A (ja) 2015-08-20
HUE036410T2 (hu) 2018-07-30
US20150315231A1 (en) 2015-11-05
ES2662500T3 (es) 2018-04-06
CA2833976A1 (en) 2008-05-29
RU2458065C2 (ru) 2012-08-10
EP2097437B1 (en) 2015-05-27
US8580983B2 (en) 2013-11-12
AU2007322423B2 (en) 2013-01-10
JP5918170B2 (ja) 2016-05-18
JP2010510210A (ja) 2010-04-02
JP2013173781A (ja) 2013-09-05
BR122013033954B1 (pt) 2021-01-12

Similar Documents

Publication Publication Date Title
MX2009005335A (es) El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
WO2008021368A3 (en) Compositions and methods for neuroprotection
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
EP2099449A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
HK1115314A1 (en) Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP1857112A4 (en) AGAINST CANCER FOR ORAL USE WITH LIPOSOME-CONTAINING PHYTOSTEROLS AND PREVENTION OR TREATMENT OF CANCER WITH LIPOSOM
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
SI2027140T1 (sl) Industrijski proces za sintezo 17 alfa -acetoksi-11 beta -(4-(n,n- dimetil-amino)-fenil)-19-norpregna-4,9-dien-3,20-diona in novi intermediati postopka
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
MX2010005345A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
WO2010091299A3 (en) Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
WO2011022838A8 (en) Polyhydroxylated bile acids for treatment of biliary disorders
IL204194A0 (en) Natural brassinosteroids for use for treating hyperproliferation, treating proliferative diseases and reducing adverse effects of steroid dysfunction in mammals, pharmaceutical composition and its use
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
PH12014501074A1 (en) Methods of using a thiazole derivative
WO2007089733A3 (en) Regimens for treatment of conditions related to estrogen deficiency
UA98938C2 (ru) Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
IL204957A (en) Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten

Legal Events

Date Code Title Description
FG Grant or registration